TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7963143
Drug: Beta-carotene administration
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene administration with high caloric content
Study: 2961357
Drug: Clodronate 400
Normalized name: clodronic acid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 400 mg/d
Study: 2961357
Drug: Clodronate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1600 mg/d
Study: 18261100
Drug: Intralesional 5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 5-fluorouracil, lidocaine, and epinephrine (5-FU+LE) - 4 mL of 50 mg/mL 5-fluorouracil and 1 mL of a mixture of 20 mg/mL [2%] lidocaine and 0.0125 mg/mL epinephrine, administered up to four times at weekly intervals.
Study: 14597516
Drug: Topical aminocaproic
Normalized name: aminocaproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aminocaproic acid (Caprogel)
Study: 8635109
Drug: CT +
Normalized name: Aveeno Protect + Hydrate SPF70 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT + RT (Cisplatin 100mg/m2 on day 1, 5-fluorouracil 1000 mg/m2 from day 1 to 5, followed by RT)
Study: 3914174
Drug: Recombinant interferon‐alpha‐2C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha‐2C monotherapy
Study: 31838879
Drug: Standard-of-care (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SC) treatment
Study: 16221950
Drug: Bee sting
Normalized name: bee sting kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee sting therapy (live bees, up to 20, administered three times per week for 24 weeks)
Study: 16221950
Drug: Bee sting
Normalized name: bee sting kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee sting therapy
Study: 12030735
Drug: Intravenous steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous steroids and aerosol bronchodilators (40 mg methylprednisolone IV, decreasing to 20 mg after 10 days, then 4 mg x 4 days; 10 mg salbutamol and 1 mg ipratropiumbromide aerosol therapy)
Study: 12030735
Drug: Oral steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroids and MDI bronchodilators (32 mg methylprednisolone orally for 1 week, then 24 mg x day(‐1) for 4 days, decreasing to 4 mg x week(‐1); 1.6 mg fenoterol and 640 microg ipratropiumbromide MDI with a spacer)
Study: 7741534
Drug: Intravenous enterostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enterostatin (D3800) 4 mg
Study: 7741534
Drug: Intravenous enterostatin
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous enterostatin (D3800) 16 mg
Study: 29536205
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of dexamethasone orally 1 hour before the procedure
Study: 29536205
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone orally 1 hour before and 24 hours after the procedure
Study: 24699466
Drug: Investigational vaccine
Normalized name: INVESTIGATIONAL VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational vaccine formulations (10 or 30μg each of dPly and PhtD, alone or in combination with PHiD-CV)
Study: 24699466
Drug: PHiD-CV (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV (licensed vaccine)
Study: 24699466
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg dPly/PhtD with PHiD-CV-conjugates
Study: 24699466
Drug: All pneumococcal
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All pneumococcal protein-containing formulations
Study: 22432716
Drug: Neurofunctional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofunctional treatment (NFT)
Study: 18190664
Drug: Buprenorphine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine maintenance treatment
Study: 12426274
Drug: Informed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Informed administration of the Chronic Respiratory Questionnaire (CRQ)
Study: 12426274
Drug: Informed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Informed administration of the St. George's Respiratory Questionnaire (SGRQ)
Study: 12426274
Drug: Blind administration
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind administration of the CRQ
Study: 12426274
Drug: Blind administration
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind administration of the SGRQ
Study: 795610
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg indomethacin twice daily
Study: 30882524
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural boluses (6-mL every 45 minutes of 0.1% ropivacaine with 2 µg/mL fentanyl)
Study: 30882524
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (8 mL/h of 0.1% ropivacaine with 2 µg/mL fentanyl)
Study: 29947142
Drug: Cognitive games
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive games group (experimental group) - card and board games training executive functions, 30-min training session twice a week for six weeks.
Study: 28513426
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (pregabalin 150-mg capsule)
Study: 28513426
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (pregabalin 150-mg capsule)
Study: 28513426
Drug: Test and
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test and Reference products (pregabalin 150-mg capsule)
Study: 22094540
Drug: Docetaxel/gemcitabine (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/gemcitabine (arm A: docetaxel 75 mg/m(2) on day 1, gemcitabine 1,000 mg/m(2) on days 1 and 8)
Study: 22094540
Drug: Docetaxel/capecitabine (arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/capecitabine (arm B: docetaxel 75 mg/m(2) on day 1, capecitabine 1,250 mg/m(2) twice daily on days 1-14)
Study: 12877614
Drug: Endovascular brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular brachytherapy (EVBT) with high-dose-rate (192)Ir irradiation (12 Gy for a reference vessel radius of 3 mm and a 2-mm reference depth)
Study: 11774060
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E supplementation (500 or 1000 mg of Vitamin C and 500 or 1000 IU of Vitamin E)
Study: 8126620
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (5 g/kg/day)
Study: 8126620
Drug: Standard-protein diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-protein diet (2.5 g/kg/day)
Study: 239281
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol in smokers
Study: 239281
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low dose of alcohol and tobacco in smokers
Study: 239281
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol in nonsmokers
Study: 239281
Drug: Smoking dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking dose of nicotine with low levels of alcohol in smokers
Study: 31545510
Drug: Mannitol in
Normalized name: mannitol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol in cardiopulmonary bypass prime solution
Study: 31439215
Drug: Ezetimibe added
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe added to statin therapy
Study: 26261033
Drug: SPC5001 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPC5001 (5 mg kg(‐1))
Study: 9403477
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (INR 3.0‐4.5)
Study: 9403477
Drug: Aspirin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (30 mg daily)
Study: 27803391
Drug: Desmoteplase (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmoteplase (90 μg/kg)
Study: 22396085
Drug: Methadone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (mean dose at delivery = 63.89 mg)
Study: 22396085
Drug: Buprenorphine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (mean dose at delivery = 14.05 mg)
Study: 19249432
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg orally twice a day before and on the day of coronary catheterization (n = 106)
Study: 19249432
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 3 g and 2 g orally before, and 2 g twice after coronary catheterization with a 12-hour interval (n = 106)
Study: 19249432
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) in patients with high dose of dye
Study: 19249432
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid in patients with high dose of dye
Study: 11573660
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with remifentanil/propofol
Study: 27922194
Drug: Pregabalin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (200 mg)
Study: 21454913
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine polacrilex chewing gum
Study: 14763919
Drug: Insulin-stimulated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated glucose uptake (ISGU) in FDR
Study: 14763919
Drug: Insulin-stimulated glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulated glucose uptake (ISGU) in controls
Study: 26255511
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) intervention with stimulation of dense-disperse wave (10 Hz/50 Hz) at Tianshu (ST 25) and Zusanli (ST 36), 0.1 to 1.0 mA, once daily for 5 times a week for 2 weeks, then 2 times a week for 2 weeks.
Study: 24015975
Drug: Ti (titanium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ti (titanium) 4.1 mm diameter implants
Study: 24015975
Drug: TiZr (titanium-zirconium)
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: TiZr (titanium-zirconium) 3.3 mm diameter implants
Study: 24015975
Drug: Both Ti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Ti and TiZr implants
Study: 21677073
Drug: Multi-micronutrient beverage
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-micronutrient beverage (250 mL/d including vitamin A, iron, and zinc)
Study: 19699832
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted educational lessons based on the Medicine Wheel Model for Nutrition (6 lessons over 6 months)
Study: 16125417
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Motor Training and Action Observation (MT + AO)
Study: 19780243
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor receptor inhibitors (tyrosine kinase inhibitors or monoclonal antibodies)
Study: 9932083
Drug: Irinotecan (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (350 mg/m2 administered over 90 minutes every 3 weeks)
Study: 3063534
Drug: Rolipram 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolipram 0.50 mg orally t.i.d. for the first three days, then 0.75 mg orally t.i.d. until day 28
Study: 3063534
Drug: Desipramine 25
Normalized name: desipramine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 25 mg orally t.i.d. for the first three days, then 50 mg orally t.i.d. until day 28
Study: 31347193
Drug: High-energy subgroup
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy subgroup (n = 14, mean 599.9 ± 136.5 J/ml)
Study: 31347193
Drug: Low-energy subgroup
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy subgroup (n = 7, mean 240.2 ± 74.6 J/ml)
Study: 30818339
Drug: Maternal antiparasitic
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maternal antiparasitic therapy during pregnancy
Study: 30818339
Drug: 10-valent S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-valent S. pneumoniae conjugate vaccine and pentavalent vaccine
Study: 29634701
Drug: Tacrolimus (0.03%)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (0.03%) eye ointment BD
Study: 26492775
Drug: Heparin, propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin, propranolol with monopril and PCI
Study: 22710021
Drug: Low-dose statin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose statin plus ezetimibe
Study: 19382492
Drug: CMC gel
Normalized name: CMC 001
DrugBank: CMC 001 (DB05353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMC gel
Study: 14980279
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids used early (<2 wk)
Study: 14980279
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids used late (>2 wk)
Study: 3120436
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg nitroglycerin
Study: 30614468
Drug: Letrozole after
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole after aromatase inhibitor-based therapy
Study: 26194634
Drug: Corneal cross-linking
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal cross-linking treatment (15 eyes)
Study: 22963506
Drug: Spironolactone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5 mg and 25 mg)
Study: 19558610
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg twice daily) in statin users (n = 22)
Study: 15636668
Drug: Tolterodine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine combined with an educational intervention (printed information and explanation about OAB, medication use, and behavioral treatments)
Study: 9404828
Drug: Heparin-induced extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-induced extracorporeal low-density lipoprotein (LDL) precipitation (HELP)
Study: 3465581
Drug: Prednisolone 40
Normalized name: prednisolone 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 40 mg/day
Study: 10624252
Drug: Patients on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on hypnotic medication
Study: 10624252
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not on hypnotic medication
Study: 2162239
Drug: Etoposide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (120 mg/m2, days 1‐3)
Study: 2162239
Drug: Etoposide plus
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide plus high-dose cisplatin (60 mg/m2, days 1‐2)
Study: 2162239
Drug: Etoposide plus
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide plus high-dose cisplatin
Study: 469108
Drug: Caffeine (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (low dose equivalent to one cup of coffee)
Study: 469108
Drug: Caffeine (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (high dose equivalent to three cups of coffee)
Study: 23168228
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (SQ group): PPI + amoxicillin for 5 days followed by PPI + clarithromycin + metronidazole for 5 days
Study: 23168228
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (AM group): PPI + amoxicillin + metronidazole for 7 days
Study: 23168228
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (AC group): PPI + amoxicillin + clarithromycin for 7 days
Study: 23168228
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (SQ group)
Study: 23168228
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (AM group)
Study: 23168228
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (AC group)
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for alliance
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for non-positive learning statements received from counselor
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for participation variables
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for self-disclosures about the past
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for group cohesion
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for degree of participation of each group member
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for positive feedback
Study: 21409739
Drug: Videotaped group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videotaped group drug counseling sessions rated for negative feedback
Study: 10741082
Drug: TIVA (Total
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA (Total Intravenous Anesthesia) using a mixture of propofol (45 ml of 1%) and alfentanil (2,500 micrograms)
Study: 2865615
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate patches
Study: 12433647
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of puerarin injection
Study: 12433647
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of anisodamine
Study: 8607174
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1.5 g twice daily (n=77)
Study: 8607174
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous steroids (IVS) 5 mg/kg for 5 days (n=73)
Study: 8607174
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous steroids (IVS)
Study: 1945993
Drug: Fenoterol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (0.25 mg/kg)
Study: 30607677
Drug: Topical FDX104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical FDX104 4% foam applied twice daily for 5 weeks
Study: 30607677
Drug: Vehicle foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle foam (placebo) applied twice daily for 5 weeks
Study: 30607677
Drug: Topical FDX104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical FDX104 4% foam
Study: 21175277
Drug: Software recommendations
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Software recommendations for insulin dosage adjustments
Study: 21175277
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy titrated every 1-4 weeks
Study: 18300511
Drug: Capsule YD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule YD
Study: 11497396
Drug: lenograstim (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lenograstim (2 microg/kg daily, s.c.)
Study: 9613651
Drug: Tetravalent rhesus
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent rhesus rotavirus vaccine (RV‐TV)
Study: 9613651
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 of RV‐TV
Study: 9613651
Drug: Dose 2
Normalized name: Fluzone High-Dose 2011-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 of RV‐TV
Study: 9613651
Drug: Dose 3
Normalized name: Dial-A-Dose 30mL Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3 of RV‐TV
Study: 9613651
Drug: Plaque purification
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plaque purification and serotyping after Dose 1
Study: 9613651
Drug: Plaque purification
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plaque purification and serotyping after Dose 2
Study: 9613651
Drug: Plaque purification
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plaque purification and serotyping after Dose 3
Study: 8021329
Drug: Fixed-dose transdermal
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose transdermal nicotine (21 or 22 mg/day for 6 weeks)